ASP5854

ASP5854 is a **novel, orally active small molecule** that acts as a **dual antagonist of adenosine A1 and A2A receptors**. It was developed for potential treatment of **Parkinson's disease** and **cognitive impairment**, and investigated for neuroprotection in ischemic stroke. By blocking both adenosine A1 and A2A receptors in the central nervous system, ASP5854 improves **motor function** and **cognition** in preclinical models, and inhibits catalepsy, a surrogate for antipsychotic-induced extrapyramidal symptoms. Preclinical studies show that ASP5854 restores striatal dopamine levels, potentiates the effects of L-DOPA, and reverses memory deficits in various animal models.

Other names

C524699C-524699C 524699ASP-5854ASP5854ASP 5854UNII-BJS8Y4IC5VUNII-BJS-8Y4IC5VUNII-BJS 8Y4IC5V